34 completed, 8 terminated, 2 active not recruiting, 2 withdrawn. 21 Phase 1, 16 Phase 2, 11 Phase 4, 4 Phase 3, 1 Not applicable.
Follow Halozyme Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism Testosterone enanthate - Hypogonadism, Male | Phase 3 | Recruiting | Halozyme Therapeutics | 100 | 2025-03-07 | 2026-02-18 |
| A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma Nivolumab + Relatlimab, rHuPH20 - Melanoma | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 579 | 2023-03-06 | 2026-08-26 |
| MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma Pegvorhyaluronidase alfa, Abraxane, Gemcitabine - Pancreatic Ductal Adenocarcinoma | Phase 2 | Withdrawn | Abramson Cancer Center at Penn Medicine | 2020-01-01 | 2020-01-31 | |
| Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma Atezolizumab, PEGPH20 - Pancreatic Ductal Adenocarcinoma | Phase 2 | Terminated | Gulam Manji | 1 | 2019-11-01 | 2020-12-23 |
| Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC PEGPH20, Pembrolizumab - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer | Phase 2 | Unknown | Pancreatic Cancer Research Team | 35 | 2019-05-01 | 2019-05-07 |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin - Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 219 | 2017-10-13 | 2026-08-03 |
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma PEGPH20, CIS, GEM - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic | Phase 1 | Terminated | Halozyme Therapeutics | 85 | 2017-10-02 | 2020-02-07 |
| Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma Gemcitabine, Nab-paclitaxel, PEGPH20 - Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma | Not applicable | Active not recruiting | Memorial Sloan Kettering Cancer Center | 110 | 2016-10-01 | 2025-11-26 |
| Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC) Eribulin mesylate, Biologic: PEGylated recombinant human hyaluronidase (PEGPH20), Biologic: PEGylated recombinant human hyaluronidase - Metastatic Breast Cancer | Phase 1 / Phase 2 | Terminated | Eisai Inc. | 25 | 2016-07-13 | 2020-07-13 |
| A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20), Placebo, nab-Paclitaxel - Pancreatic Ductal Carcinoma | Phase 3 | Terminated | Halozyme Therapeutics | 492 | 2016-03-14 | 2020-07-14 |
| Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase Cohort 1: bococizumab 150 mg + rHuPH20, Cohort 2: bococizumab 300 mg, Cohort 3: bococizumab 300 mg + rHuPH20 - Healthy, Hypercholesterolemia | Phase 1 | Terminated | Pfizer | 60 | 2016-02-01 | 2016-10-21 |
| A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors PEGPH20, Pembrolizumab - NSCLC, Gastric Cancer | Phase 1 | Completed | Halozyme Therapeutics | 56 | 2015-10-22 | 2020-02-07 |
| A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC PEGylated recombinant human hyaluronidase PH20, Docetaxel - Non-small Cell Lung Cancer | Phase 1 | Terminated | Halozyme Therapeutics | 16 | 2015-02-10 | 2019-02-08 |
| S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer PEGPH20, Oxaliplatin, Leucovorin - Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Completed | SWOG Cancer Research Network | 126 | 2014-01-23 | 2024-02-09 |
| A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20) Rapid Acting insulin with pre-treatment of rHuPH20, Sham injection - Type 1 Diabetes Mellitus | Phase 4 | Completed | Halozyme Therapeutics | 14 | 2013-10-03 | 2019-02-01 |
| PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer PEGPH20, Nab-paclitaxel, Gemcitabine - Metastatic Pancreatic Cancer | Phase 2 | Completed | Halozyme Therapeutics | 279 | 2013-05-14 | 2020-07-20 |
| CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM) Commercial Hylenex® recombinant (hyaluronidase human injection), Precommercial Hylenex recombinant (hyaluronidase human injection), Insulin lispro - Type 1 Diabetes Mellitus | Phase 4 | Completed | Halozyme Therapeutics | 456 | 2013-03-01 | 2018-11-07 |
| Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers Ondansetron, Ondansetron + Hylenex, Zofran ODT - Healthy | Phase 1 | Completed | Halozyme Therapeutics | 12 | 2012-02-01 | 2014-01-24 |
| Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase Sham Injection, Recombinant human hyaluronidase PH20, Insulin aspart - Type 1 Diabetes Mellitus | Phase 4 | Completed | Halozyme Therapeutics | 25 | 2011-12-01 | 2019-02-26 |
| A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase CINRYZE with rHuPH20 - Hereditary Angioedema | Phase 2 | Completed | Shire | 12 | 2011-09-12 | 2021-07-19 |
Showing 20 of 48. Sign in to see all of them.
Insulin Resistance (8) · Diabetes Mellitus, Type 1 (7) · Dehydration (5) · Pancreatic Neoplasms (4) · Diabetes Mellitus (3) · Neoplasm Metastasis (3) · Carcinoma, Pancreatic Ductal (2) · Diabetes Mellitus, Type 2 (2) · Neoplasms (2) · Non-Muscle Invasive Bladder Neoplasms (2) · Adenocarcinoma (1) · Angioedemas, Hereditary (1) · Arthritis, Rheumatoid (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1)
PEGPH20 (15) · Insulin Lispro (12) · Insulin (6) · Insulin Aspart (6) · Gemcitabine (5) · insulin glulisine (4) · 130-nm albumin-bound paclitaxel (3) · Albumin-Bound Paclitaxel (3) · Insulin Glargine (3) · Insulin, Regular, Human (3) · Sodium Chloride (3) · atezolizumab (3) · Fluorouracil (2) · Hyaluronoglucosaminidase (2) · Leucovorin (2)
United States (42) · Australia (3) · Belgium (3) · Israel (3) · South Korea (3) · Spain (3) · United Kingdom (3) · Brazil (2) · Canada (2) · Czechia (2) · France (2) · Germany (2) · Italy (2) · Poland (2) · Taiwan (2)
Douglas Muchmore, M.D. (3) · George Harb, MD, MPH (3) · George E Harb, MD (2) · Joy Zhu, M.D. (2) · Linda A Morrow, M.D. (2) · Linda Morrow, MD (2) · Marcus Hompesch, M.D. (2) · Anoshie Ratnayake, M.D. (1) · Coburn H Allen, MD (1) · Donald Lamm, M.D. (1) · Douglas Muchmore, MD (1)
PMID 19459762, PMID 19805455, PMID 19819665, PMID 19819667, PMID 19947907, PMID 21273493, PMID 21714645, PMID 22136324, PMID 23043164, PMID 23062548, PMID 24486335, PMID 29232172, PMID 30623096, PMID 30817250, PMID 33478521, PMID 33982408, PMID 36940261, PMID 41449151
2015 (3), 2016 (1), U10CA180888 (1)